2022
Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors
Chen Q, Lu L, Ma W. Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors. Cancers 2022, 14: 5983. PMID: 36497465, PMCID: PMC9739567, DOI: 10.3390/cancers14235983.Peer-Reviewed Original ResearchCAR T-cell therapyT-cell therapyCAR T cellsT cellsSolid tumorsChimeric antigen receptor T-cell therapyAdequate T-cell responsesCytokine release syndromeHalf of patientsT cell responsesTumor antigen targetsRelease syndromeAdoptive immunotherapyClinical efficacyHeterogeneous solid tumorsHematological malignanciesSide effectsTarget antigenAntigen targetsTherapyTumorsCancer treatmentNon-cancer cellsCancer cellsEfficacyAsparagine, colorectal cancer, and the role of sex, genes, microbes, and diet: A narrative review
Shen X, Jain A, Aladelokun O, Yan H, Gilbride A, Ferrucci LM, Lu L, Khan SA, Johnson CH. Asparagine, colorectal cancer, and the role of sex, genes, microbes, and diet: A narrative review. Frontiers In Molecular Biosciences 2022, 9: 958666. PMID: 36090030, PMCID: PMC9453556, DOI: 10.3389/fmolb.2022.958666.Peer-Reviewed Original ResearchColorectal cancerCRC patientsNarrative reviewSex steroid hormone estrogenFemale CRC patientsAnti-tumor effectsPI3K/Akt/Sex-related influencesSex-related factorsAsparagine synthetase expressionSex-specific factorsClinical outcomesTumor burdenCRC progressionPoor prognosisHormone estrogenEstrogen receptorSOX12 expressionRole of sexTherapeutic useAkt/Cancer cellsSynthetase expressionL-asparaginasePatientsBreast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
Yao L, Jia G, Lu L, Ma W. Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies? Current Oncology 2022, 29: 4902-4913. PMID: 35877249, PMCID: PMC9320700, DOI: 10.3390/curroncol29070389.Peer-Reviewed Original ResearchConceptsNeoadjuvant chemotherapyBreast cancer patientsCancer patientsEfficacy of NACHuman leukocyte antigen-DR isotypeInitiation of therapyTumor-infiltrating lymphocytesBenefits of treatmentTumor-associated macrophagesOncotype DXMolecular testingPatientsDecreased levelsCancer cellsChemotherapyTreatmentMammaPrintSurgeryLymphocytesTherapyTumorsMacrophagesValeric acid acts as a novel HDAC3 inhibitor against prostate cancer
Han R, Yang H, Li Y, Ling C, Lu L. Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer. Medical Oncology 2022, 39: 213. PMID: 36175803, PMCID: PMC9522682, DOI: 10.1007/s12032-022-01814-9.Peer-Reviewed Original ResearchConceptsProstate cancer cellsProstate cancerHDAC3 inhibitorCancer cellsCancer-related deathAnti-cancer effectsVivo mouse modelAnti-cancer efficacyAnti-cancer activityMouse modelNew agentsSecond causeHDAC inhibitorsCancerNormal cellsInhibitorsValeric acidCellsCASP3 activityCulture systemDiseaseChemosensitizers
2020
Hot Spot TERT Promoter Mutations Are Rare in Sporadic Pancreatic Neuroendocrine Neoplasms and Associated with Telomere Length and Epigenetic Expression Patterns
Posch A, Hofer-Zeni S, Klieser E, Primavesi F, Naderlinger E, Brandstetter A, Filipits M, Urbas R, Swiercynski S, Jäger T, Winkelmann P, Kiesslich T, Lu L, Neureiter D, Stättner S, Holzmann K. Hot Spot TERT Promoter Mutations Are Rare in Sporadic Pancreatic Neuroendocrine Neoplasms and Associated with Telomere Length and Epigenetic Expression Patterns. Cancers 2020, 12: 1625. PMID: 32575418, PMCID: PMC7352723, DOI: 10.3390/cancers12061625.Peer-Reviewed Original ResearchTelomerase reverse transcriptase (TERT) promoter mutationsPancreatic neuroendocrine neoplasmsSporadic pancreatic neuroendocrine neoplasmsT allele frequencyC250TNeuroendocrine neoplasmsPNEN casesReverse transcriptase (TERT) promoter mutationsDisease-free survivalTrue clinical valueLarge patient cohortPromoter mutationsTERT promoter mutationsParaffin-embedded tissuesPNEN patientsTPM statusClinicopathological informationPatient cohortClinical valueHigh incidenceCancer subtypesAllele frequenciesRelative TLTelomere maintenance mechanismCancer cells
2019
MicroRNA-34a suppresses aggressiveness of hepatocellular carcinoma by modulating E2F1, E2F3, and Caspase-3
Han R, Chen X, Li Y, Zhang S, Li R, Lu L. MicroRNA-34a suppresses aggressiveness of hepatocellular carcinoma by modulating E2F1, E2F3, and Caspase-3. Cancer Management And Research 2019, 11: 2963-2976. PMID: 31114344, PMCID: PMC6489561, DOI: 10.2147/cmar.s202664.Peer-Reviewed Original ResearchPrimary hepatocellular carcinomaHepatocellular carcinomaKaplan-Meier survival curvesNormal tissuesSNU-449Cell proliferationLiver cancer cellsQuantitative reverse transcription PCROverall survivalPatient survivalCaspase-3 activityHCC patientsReverse transcription-PCRAntineoplastic roleBetter survivalTreatment groupsTumor aggressivenessRT-qPCR resultsSurvival analysisSurvival curvesMeta-AnalysisCASP3 activityMicroRNA-34aCancer cellsCell invasion
2018
Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer
Chen Q, Yao L, Burner D, Minev B, Lu L, Wang M, Ma W. Epithelial membrane protein 2: a novel biomarker for circulating tumor cell recovery in breast cancer. Clinical And Translational Oncology 2018, 21: 433-442. PMID: 30218306, DOI: 10.1007/s12094-018-1941-1.Peer-Reviewed Original ResearchConceptsEpithelial membrane protein-2MDA-MB-231 cellsBreast cancerBreast cancer cellsNovel biomarkersMCF7 cellsCancer cellsAnti-pan cytokeratinPrimary breast cancerBreast cancer patientsMesenchymal transition eventsPatient blood samplesTumor cell recoveryFlow cytometric assayCTC countCancer patientsHealthy donorsBlood samplesMembrane protein 2Cytometric assayTumor cellsEMP2 expressionCancerCell spikingBiomarkers
2017
Artificial human antigen‐presenting cells are superior to dendritic cells at inducing cytotoxic T‐cell responses
Li H, Shao S, Cai J, Burner D, Lu L, Chen Q, Minev B, Ma W. Artificial human antigen‐presenting cells are superior to dendritic cells at inducing cytotoxic T‐cell responses. Immunology 2017, 152: 462-471. PMID: 28664991, PMCID: PMC5629434, DOI: 10.1111/imm.12783.Peer-Reviewed Original ResearchMeSH KeywordsAntigen PresentationCancer VaccinesCell SurvivalCytotoxicity, ImmunologicDelayed-Action PreparationsDendritic CellsDrug CompoundingDrug LiberationHumansInhibitor of Apoptosis ProteinsKineticsLactic AcidLipopolysaccharidesMART-1 AntigenMCF-7 CellsNanoparticlesNeoplasmsPeptide FragmentsPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerSolubilitySurvivinT-Lymphocytes, CytotoxicConceptsArtificial antigen-presenting cellsCytotoxic T lymphocytesT cell responsesDendritic cellsAntigen-presenting cellsTumor antigenic peptidesCTL responsesMature DCsT cellsAntigen-specific cytotoxic T lymphocytesAntigen-specific CTL responsesHuman antigen-presenting cellsCytotoxic T cell responsesHuman immature dendritic cellsEffective T cell responsesAntigenic peptidesEffective CTL responsesTumor antigen presentationCancer cellsImmature dendritic cellsMature dendritic cellsT-cell immunotherapyMHC class IMHC class I-peptide complexesWarrants further assessment
2016
Metformin alters DNA methylation genome-wide via the H19/SAHH axis
Zhong T, Men Y, Lu L, Geng T, Zhou J, Mitsuhashi A, Shozu M, Maihle NJ, Carmichael GG, Taylor HS, Huang Y. Metformin alters DNA methylation genome-wide via the H19/SAHH axis. Oncogene 2016, 36: 2345-2354. PMID: 27775072, PMCID: PMC5415944, DOI: 10.1038/onc.2016.391.Peer-Reviewed Original ResearchConceptsS-adenosylhomocysteine hydrolaseDNA methylation genomeGenome-wide alterationsNovel mechanismSubset of genesDNA methyltransferase 3BMethylation genomeDNA methylationEpigenetic dysregulationPathway genesMolecular basisAMPK activationLet-7Methyltransferase 3BMolecular mechanismsEndometrial cancer tissue samplesH19 knockdownGene methylationCell proliferationCancer tissue samplesCancer cellsNormal cellsConcomitant inhibitionGenesMethylation
2010
Let-7a regulation of insulin-like growth factors in breast cancer
Lu L, Katsaros D, Zhu Y, Hoffman A, Luca S, Marion CE, Mu L, Risch H, Yu H. Let-7a regulation of insulin-like growth factors in breast cancer. Breast Cancer Research And Treatment 2010, 126: 687-694. PMID: 20848182, DOI: 10.1007/s10549-010-1168-5.Peer-Reviewed Original ResearchConceptsIGF expressionBreast cancerOvarian cancerInsulin-like growth factorDisease-free survivalCancer cellsAction of IGFBreast cancer patientsExpression of IGFHigh-grade tumorsIGF-II expressionPR-negative cancerLet-7aQuantitative methylation-specific PCRBreast cancer samplesOverall survivalFavorable prognosisPatient survivalCancer patientsGrade tumorsIGF mRNAsMethylation-specific PCRDisease featuresCancerCancer samples